Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fibrobody Small Molecule Conjugate (IPF)
- Development stage
- Preclinical
- Lead developer
- Linxis Biopharmaceuticals
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Fibrobody Small Molecule Conjugate (IPF) is an experimental targeted therapeutic being developed by Linxis Biopharmaceuticals for the treatment of Interstitial Pulmonary Fibrosis (IPF). The drug candidate is built upon the proprietary Fibrobody® platform, which utilizes high-affinity antibody fragments (VHH or nanobodies) to specifically target Platelet-Derived Growth Factor Receptor Beta (PDGFRB). PDGFRB is a cell-surface receptor that is highly upregulated on activated myofibroblasts, the primary cells responsible for the excessive extracellular matrix deposition characteristic of fibrotic diseases. By conjugating a therapeutic small molecule payload to the PDGFRB-targeting Fibrobody, the agent is designed to deliver the treatment directly to the site of pulmonary fibrosis, potentially enhancing local efficacy while reducing systemic toxicity. The program is currently in the discovery stage of development.
- Brand names
- Fibrobody
- Other names
- Fibrobody Small Molecule Conjugate
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on Fibrobody Small Molecule Conjugate (IPF).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fibrobody Small Molecule Conjugate (IPF).